Research peptides · For laboratory and scientific research in vitro · Not medications · Not approved for consumption · Adults only (18+)
Methylene Blue — mitochondrial electron carrier
In short
Improves memory and focus by directly boosting energy production in your cells and brain.
Overview
Methylene blue is the active ingredient (methylthioninium chloride) in research-grade USP material. It is one of the oldest synthetic compounds in pharmacology — first synthesized in 1876 by Heinrich Caro. The compound's redox-active phenothiazine core can shuttle electrons in cellular respiration, lending it both diagnostic (urine staining, antidote properties) and investigational metabolic uses.
Methylene blue alternates between reduced (leuco-MB) and oxidized (MB+) forms with a midpoint potential of ~+11 mV, positioning it as an electron carrier compatible with mitochondrial complex I bypass. The compound also has MAO inhibition activity at low micromolar concentrations and binds to amyloid β oligomers in research models — making it a frequent subject in neurodegenerative research.
Molecular information
Нежеланите събития при ниски дози обикновено са минимални: синя/зелена урина, преходно гадене, синьо оцветяване на лигавиците. При по-високи дози или при едновременна употреба на серотонергични медикаменти, MAO инхибирането може да предизвика серотонинов синдром — противопоказание, което изследователите трябва да зачитат. Метиленовото синьо е противопоказано при G6PD дефицит поради риск от хемолиза.
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Information about Methylene Blue is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
5-Amino-1MQ
5-Amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase), identified by Anthony Sauve (Cornell) in 2018. NNMT is a "metabolic sink" for methyl donors and NAD+ — suppressing it in adipocytes raises energy expenditure without reducing calorie intake.
ReadAdipotide
Adipotide is a target peptide developed by Wadih Arap and Renata Pasqualini (MD Anderson) for selective elimination of white adipose tissue. It binds prohibitin on adipocyte vasculature and induces apoptosis of the blood vessels supplying fat tissue — leading to nonsurgical fat reduction.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadARA-290
ARA-290 (Cibinetide) is an 11-amino-acid fragment of erythropoietin (EPO) developed by Anthony Cerami as a cytoprotective molecule without erythropoietic activity. It retains the tissue-protective effects of EPO without raising hematocrit — explaining its potential in diabetic neuropathy and cardiac applications.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadBPC-157
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice — hence the name Body Protection Compound. Over thirty years of research by Predrag Sikiric's group at the University of Zagreb (100+ peer-reviewed papers) establish its angiogenic action through the VEGFR2 receptor and its stimulation of fibroblasts. If you work with in vitro models of tendon, muscle or gut tissue, BPC-157 is among the most extensively documented regenerative peptides.
ReadNo comments yet. Be the first.
Comments are reviewed before publishing.
